March 26, 2013
Mallinckrodt, the Pharmaceutical business of Covidien, has provided an update on the molybdenum-99 (Mo-99) supply outlook. They have made extensive efforts, at substantial cost, in order to improve their expected Mo-99.
For the single week of April 21, Mallinckrodt’s expectations for reduced Tc-99m generator production estimates on some days are shown on the customer calendar letter attached.
Mallinckrodt continues their outreach to several domestic and international government agencies and regulatory bodies, as well as Mo-99 supply chain providers, to provide longer term mo-99 supply.
SNMMI will keep you up-to-date on upcoming information.